Literature DB >> 11459659

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

A J Barker1, K H Gibson, W Grundy, A A Godfrey, J J Barlow, M P Healy, J R Woodburn, S E Ashton, B J Curry, L Scarlett, L Henthorn, L Richards.   

Abstract

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11459659     DOI： 10.1016/s0960-894x(01)00344-4

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  72 in total

Review 1.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

2.  Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells.

Authors:  R Yerbes; A López-Rivas; M J Reginato; C Palacios
Journal:  Cell Death Differ       Date:  2012-06-22       Impact factor: 15.828

3.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

4.  Gefitinib potentiates myeloid cell differentiation by ATRA.

Authors:  M B Miranda; R Duan; S M Thomas; J R Grandis; R L Redner; J E Jones; D E Johnson
Journal:  Leukemia       Date:  2008-02-28       Impact factor: 11.528

5.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

Authors:  Cai-Hong Yun; Titus J Boggon; Yiqun Li; Michele S Woo; Heidi Greulich; Matthew Meyerson; Michael J Eck
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

6.  A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  G Goss; H Hirte; W H Miller; I A J Lorimer; D Stewart; G Batist; D A E Parolin; P Hanna; S Stafford; J Friedmann; W Walsh; S Mathews; L Douglas; L K Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

7.  Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

Authors:  A Jimeno; C Grávalos; P Escudero; I Sevilla; M E Vega-Villegas; V Alonso; I Juez; R García-Carbonero; H Bovio; R Colomer; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

8.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

9.  The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.

Authors:  Mohamed M Mohyeldin; Mohamed R Akl; Abu Bakar Siddique; Hossam M Hassan; Khalid A El Sayed
Journal:  Biochem Pharmacol       Date:  2016-12-08       Impact factor: 5.858

10.  New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres.

Authors:  Rebecca Robinson; James P Bertram; Jill L Reiter; Erin B Lavik
Journal:  J Microencapsul       Date:  2010-05       Impact factor: 3.142
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.